Gaze Bio Reveals Technology Performance for Early Diagnosis of Lung Cancer at World Society of Lung Cancer
Sep 05, 2024
A molecular diagnostics company specializing in dielectric-based molecular diagnostics 'See-Sun Biomaterials (CEO Park Hee-kyung, hereinafter referred to as See-Bio)' will participate in the 'World Conference on Lung Cancer (WCLC)' to be held in San Diego from September 7th to 10th. Through this, we will announce the results of clinical trials of our newly developed product 'Epi-TOPTM LUNG assay'.
The World Lung Cancer Society is a global academic conference involving about 10,000 experts worldwide. In particular, it is widely known as the world's largest academic conference specializing in the study of lung cancer and other chest malignancies.
At this conference, Siouxin Bio will present the results of a prospective clinical study of the 'Epi-TOPTM LUNG assay' product being developed as a medical device for early diagnosis of lung cancer. For this study, Shi's Bio focused on proving the excellent diagnostic performance of the product in collaboration with Konkuk University's Precision Medical Lung Cancer Center.
'Epi-TOPTM LUNG assay' is a product developed through the unique original technology of Siksa Bio, 'Epi-TOP Methylation Detection Method' and 'Cancer-specific epigenetic panel'. In addition, bronchial alveolar lavage liquid (BALF) is used to check DNA methylation patterns of specific lung cancer biomarkers so that lung cancer can be screened and diagnosed early. Sisang Bio already obtained the export license for the product in August. In addition, intellectual property rights related to commercialization have also been secured.
This clinical study, which will be presented by Sisang Bio, is the result of a prospective clinical trial that has been in progress since April. There are about 300 clinical specimens to be studied. As a result of the study, the sensitivity and specificity of 'Epi-TOPTM LUNG assay' were 93% and 94%, respectively, showing very good lung cancer diagnosis performance. In particular, it is evaluated that it showed high specificity in diagnosis of early cancer patients. This is a result that exceeds the first clinical results announced last year, 82% sensitivity and 92% specificity.
Above all, this announcement is expected to serve as an important opportunity to publicize the innovative technology of Sisang Bio to the international stage and to expand its business in the global market.
"Lung cancer is a tissue organ with a high incidence of cancer among all human organs, and the 5-year survival rate after onset is not high, and the recurrence rate is high even after initial treatment, so early diagnosis is important," said Park Hee-kyung, CEO of Shi's Bio. "To meet these needs of the market, we developed the 'Epi-TOPTM LUNG assay'."," he said.
CEO Park then added, "Through this participation in the World Lung Cancer Society, we will inform the business feasibility of the excellent epigenome analysis technology of Si-Sa-Bio and present the possibility that the independent technology-based 'Epi-TOPTM LUNG assay' can accurately select early lung cancer patients and provide more treatment opportunities."
The World Lung Cancer Society is a global academic conference involving about 10,000 experts worldwide. In particular, it is widely known as the world's largest academic conference specializing in the study of lung cancer and other chest malignancies.
At this conference, Siouxin Bio will present the results of a prospective clinical study of the 'Epi-TOPTM LUNG assay' product being developed as a medical device for early diagnosis of lung cancer. For this study, Shi's Bio focused on proving the excellent diagnostic performance of the product in collaboration with Konkuk University's Precision Medical Lung Cancer Center.
'Epi-TOPTM LUNG assay' is a product developed through the unique original technology of Siksa Bio, 'Epi-TOP Methylation Detection Method' and 'Cancer-specific epigenetic panel'. In addition, bronchial alveolar lavage liquid (BALF) is used to check DNA methylation patterns of specific lung cancer biomarkers so that lung cancer can be screened and diagnosed early. Sisang Bio already obtained the export license for the product in August. In addition, intellectual property rights related to commercialization have also been secured.
This clinical study, which will be presented by Sisang Bio, is the result of a prospective clinical trial that has been in progress since April. There are about 300 clinical specimens to be studied. As a result of the study, the sensitivity and specificity of 'Epi-TOPTM LUNG assay' were 93% and 94%, respectively, showing very good lung cancer diagnosis performance. In particular, it is evaluated that it showed high specificity in diagnosis of early cancer patients. This is a result that exceeds the first clinical results announced last year, 82% sensitivity and 92% specificity.
Above all, this announcement is expected to serve as an important opportunity to publicize the innovative technology of Sisang Bio to the international stage and to expand its business in the global market.
"Lung cancer is a tissue organ with a high incidence of cancer among all human organs, and the 5-year survival rate after onset is not high, and the recurrence rate is high even after initial treatment, so early diagnosis is important," said Park Hee-kyung, CEO of Shi's Bio. "To meet these needs of the market, we developed the 'Epi-TOPTM LUNG assay'."," he said.
CEO Park then added, "Through this participation in the World Lung Cancer Society, we will inform the business feasibility of the excellent epigenome analysis technology of Si-Sa-Bio and present the possibility that the independent technology-based 'Epi-TOPTM LUNG assay' can accurately select early lung cancer patients and provide more treatment opportunities."
|
bellho@sportschosun.com
